Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Bristol-Myers Squibb | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Bristol-Myers Squibb

Plavix sales continue to roll, while Sprycell, Baraclude and Orencia grow

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Bristol-Myers Squibb 4Q10

4Q Revenues: $5.1 billion (+2%)

4Q Earnings: $483 million (-94%)*

FY Revenues: $19.5 billion (+4%)

FY Earnings: $3.1 billion (-71%)*

Comments: U.S. sales rose 5% to $3.3 billion in 4Q10, while international sales dropped 5% to $1.8 billion (2% was due to currency exchange rates). 4Q10 Pharma sales were led by Plavix ($1.7 billion / +6%) and Abilify ($700 million / flat). The biggest gains were posted by Sprycel (+42% to $169 million), Baraclude (+25% to $264 million), and Orencia (+20% to $202 million). For the year, Plavix posted sales of $6.7 billion (+8%), while Abilify dropped slightly to $2.6 billion. Avapro/Avalide sales in 4Q10 were down 26% after a large-scale recall.

* Net earnings in 4Q09 and FY09 were boosted by $7.2 billion after-tax gain from spin-off of Mead Johnson Nutrition Co.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters